A New Era of Migraine Management: The Changing Landscape of Prevention

Please Log In or Register to continue.

Release Date: August 22, 2018
Expiration Date: August 22, 2019

Expected time to complete this activity as designed: 90 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Dodick, Dr. Friedman, and Dr. Charles will highlight the challenges currently encountered by patients and clinicians when implementing preventive treatment for migraine. They will also share with you the promising new therapies on the horizon and how they compare with currently available therapies. Presentations will include insights and understanding about how these new therapies work, the unique features of the CGRP monoclonal antibodies, how these new and emerging agents have performed in clinical trials, and, most importantly, how they may impact clinical practice and the lives of our patients. You will hear from a chronic migraineur as she shares her 50-year journey through a myriad of treatments. She will share her perspective on navigating life with migraines and what finally provided her with relief.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including neurologists, primary care physicians, nurses, pharmacists and other allied healthcare professionals who provide care to patients with headache disorders.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the most common reasons why migraine prevention fails in the clinical practice setting
  • Outline the current state of knowledge concerning the pathophysiology of calcitonin gene-related peptide (CGRP) and its role in migraine development, treatment, and prevention
  • Identify the progress to date of emerging CGRP-receptor antagonists studied in the treatment of episodic and chronic migraine prevention
  • Apply guidance and recommendations concerning the practical use of CGRP-receptor antagonists in migraine prevention, as learned from clinical trials and practical clinical experience

Agenda

Migraine Preventive Treatment Today: The Dawn of a New Era in Migraine Management – Deborah I. Friedman, MD, MPH, FAAN

The Pathophysiology of Migraine: The Science Behind the New Era in Preventive Treatment of Migraine – Andrew C. Charles, MD

Practical Strategies for Navigating Today’s New Era in Preventive Treatment of Migraine – David W. Dodick, MD

Instructions for Participation and Credit

This activity is eligible for credit through August 22, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Andrew C. Charles, MD
Professor of Neurology
UCLA School of Medicine
Los Angeles, California

Dr. Andrew Charles received his medical degree from the University of California, Los Angeles (UCLA). He completed his neurology residency training and did a neuropharmacology research fellowship at UCLA before joining the faculty full-time in 1992. Dr. Charles is currently a Professor of Neurology at the UCLA School of Medicine, where he holds the Meyer and Renee Luskin Chair in Migraine and Headache Studies. He is also Director of the UCLA Goldberg Migraine Program, which includes basic and clinical research, education, and care of patients with headache disorders. His laboratory focuses on cellular and pharmacological mechanisms of migraine and pain, with a particular interest in the development of novel therapies. Dr. Charles is an associate editor of the journal Cephalalgia, and he has served on the Board of Trustees of the International Headache Society. He currently holds the position of Secretary of the American Headache Society.

David W. Dodick, MD
Professor of Neurology
Mayo Clinic
Phoenix, Arizona

Dr. David Dodick is a Professor of Neurology at the Mayo Clinic College of Medicine and a consultant in neurology at the Mayo Clinic in Scottsdale, Arizona, as well as the Past-President of the American Headache Society. He is the Program Director of the Mayo Clinic Neurology Residency Program and Headache Medicine Fellowship Program, and the Director of the Headache Program and the Sports Neurology and Concussion Program at Mayo Clinic in Arizona. In addition, Dr. Dodick is an Adjunct Professor and International Chair of Headache in the Department of Neurosciences, Norwegian University of Science and Technology. Dr. Dodick is also President of the International Headache Society, and Chair of the American Migraine Foundation.

Deborah I. Friedman, MD, MPH, FAAN
Professor of Neurology & Neurotherapeutics
Professor of Ophthalmology
University of Texas Southwestern Medical Center
Dallas, Texas

Dr. Deborah Friedman received her medical degree at Tulane University School of Medicine. She completed her neurology residency at Baylor College of Medicine, and a neuro-ophthalmology clinical and research fellowship at the University of Southern California. In addition, she has a master’s degree in Public Health from the University of Rochester with a focus on clinical research. Dr. Friedman is a Professor of Neurology & Neurotherapeutics and Ophthalmology at the University of Texas Southwestern Medical Center, where she directs the Headache and Facial Pain Program and the Integrated Project Team for Intracranial Pressure Disorders.

Dr. Friedman is board certified in neurology and headache medicine. She is a fellow of several professional organizations and serves on the Board of Directors of the American Headache Society. She is an associate editor of Headache. Dr. Friedman has published numerous journal articles book chapters related to headache disorders, including migraine and idiopathic intracranial hypertension. Her key interests are disorders of intracranial pressure, cluster headache, and migraine.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-026-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 18-026-080

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Andrew Charles has received honoraria as a consultant from Alder BioPharmaceuticals Inc., Amgen Inc., Biohaven Pharmaceuticals, Eli Lilly and Company, and eNeura Inc. He has received grant support related to research activities from Takeda Oncology.

Dr. David Dodick has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., Autonomic Technologies, Inc., Biocentric Health, Biohaven Pharmaceuticals, Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, eNeura Inc., GBS Ventures, Insys Therapeutics, Inc., Magellan BioScience Group, Inc., Merck & Co., Inc., Pfizer Inc., Promius Pharma, LLC., TEVA Pharmaceutical LTD, Tonix Pharmaceuticals Holding Corp., Trigemina, Inc., Xenon Pharmaceuticals Inc., and Zosano Pharma Corporation. He has received royalties from Cambridge University Press and Oxford University Press. Dr. Dodick has stock options with EPIEN Medical, Inc., GBS/Nocira, and Mobile Health, and has a consulting use agreement with NAS. He holds a board position at King-Devick Technologies, Inc.

Dr. Deborah Freidman has received honoraria related to formal advisory activities from Alder BioPharmaceuticals Inc., Amgen Inc., Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, electroCore, LLC, Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; speakers’ bureau activities from Allergan, Inc., Amgen Inc., Avanir, and Supernus; as well as consultant fees from Avanir, electroCore, Eli Lilly and Company, and Promius Pharma, LLC. She has received grant support related to research activities from Autonomic Technologies, Inc., Axonoptics, Eli Lilly, Merck & Co., Inc., Teva, and Zosano. Dr. Freidman is on the Board of Directors of the American Headache Society and the Spinal CSF Leak Foundation.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Teva Pharmaceuticals

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.